View PDF Version
In the Supreme Court of the United StatesAMERICAN HOME PRODUCTS CORPORATION,
MARCELO A. FERRARI, ET AL.
ON PETITION FOR A WRIT OF CERTIORARI
TO THE SUPREME COURT OF GEORGIA
BRIEF FOR THE UNITED STATES AS AMICUS CURIAE
Counsel of Record
Assistant Attorney General
EDWIN S. KNEEDLER
Deputy Solicitor General
BENJAMIN J. HORWICH
Assistant to the Solicitor
MICHAEL S. RAAB
IRENE M. SOLET
Department of Justice
Washington, D.C. 20530-0001
The National Childhood Vaccine Injury Act of 1986 provides that "[n]o vaccine manufacturer shall be liable in a civil action" for any injury that "resulted from side effects that were unavoidable even though the vaccine was properly prepared and was accompanied by proper directions and warnings." 42 U.S.C. 300aa-22(b)(1). The question presented is whether that provision preempts state law claims against a vaccine manufacturer based on alleged defects in the design of a vaccine subject to the Act.
In the Supreme Court of the United States
No. 08-1120AMERICAN HOME PRODUCTS CORPORATION,
MARCELO A. FERRARI, ET AL.ON PETITION FOR A WRIT OF CERTIORARI
BRIEF FOR THE UNITED STATES AS AMICUS CURIAE
This brief is filed in response to the Court's order inviting the Solicitor General to express the views of the United States. In the view of the United States, because of mootness concerns, the petition for a writ of certiorari should be held pending the disposition of Bruesewitz v. Wyeth, Inc., petition for cert. pending, No. 09-152 (filed Aug. 4, 2009), or be denied. The Court should grant the petition for a writ of certiorari in Bruesewitz, which presents the same question.
Respondents brought this action in Georgia state court against petitioners, the manufacturers of vaccines administered to respondents' son. The suit alleged that the vaccines caused respondents' son to suffer neurolog ical injuries because they contained the preservative thimerosal. The trial court dismissed respondents' design defect claims as preempted by the National Child hood Vaccine Injury Act of 1986 (Vaccine Act or Act), Pub. L. No. 99-660, Tit. III, 100 Stat. 3755 (42 U.S.C. 300aa-1 et seq.). The Supreme Court of Georgia ulti mately reinstated the claims.
1. "[T]wo overriding concerns" prompted the Act: "the inadequacy-from both the perspective of vaccine- injured persons as well as vaccine manufacturers-of [a tort-based] approach to compensating those who have been damaged by a vaccine," and "the instability and unpredictability of the childhood vaccine market" due to vaccine manufacturers' fear of tort liability. H.R. Rep. No. 908, 99th Cong., 2d Sess. 7 (1986) (1986 Report). Accordingly, the Act is designed to encourage "develop ment and distribution of vaccines that will further en hance the public health" (particularly those recom mended for routine administration to children), and to compensate individuals injured by such vaccines by means other than tort law. Ibid.
The Act does so by, inter alia, establishing a Na tional Vaccine Advisory Committee, funding vaccine research, promoting dissemination of information on vaccines, and collecting data on adverse events related to vaccine administration. 42 U.S.C. 300aa-5, 300aa-6(b), 300aa-25, 300aa-26, 300aa-28. Compensation for injuries comes primarily from the National Vaccine Injury Com pensation Program, which offers "no-fault" monetary awards to individuals who suffer injuries causally associ ated with particular childhood vaccines. See Shalala v. Whitecotton, 514 U.S. 268 (1995). The program is funded by Congressional appropriations and an excise tax on each vaccine dose. 42 U.S.C. 300aa-10 to 300aa-19; 26 U.S.C. 4131.
To receive compensation for a vaccine-related injury or death, the injured party (or his legal representative) must file a petition in the Court of Federal Claims (CFC), naming the Secretary of Health and Human Ser vices (Secretary) as respondent. 42 U.S.C. 300aa-11(a), 300aa-12(a) and (b). The claimant need show by a pre ponderance of the evidence only that he received a vac cine listed on the "Vaccine Injury Table"1 and suffered a corresponding listed injury, or that a listed vaccine in fact caused or significantly aggravated any injury. 42 U.S.C. 300aa-11(c), 300aa-13(a). The claimant does not need to establish any defect in the vaccine or fault on the part of the manufacturer.
A petition for compensation is initially heard by a special master appointed by the CFC, whose decision is reviewable by the CFC, and in turn by the Federal Cir cuit. 42 U.S.C. 300aa-12(c)-(f). Awards cover medical costs, lost earning capacity, and pain and suffering. 42 U.S.C. 300aa-15(a). To ensure representation, the Compensation Program awards reasonable attorneys' fees even if there is no award to the claimant, provided the petition was brought in good faith on a reasonable basis. 42 U.S.C. 300aa-15(e).
The Act forbids a claimant from resorting immedi ately to a civil action for damages against the vaccine's manufacturer. Rather, he must first file a petition un der the no-fault scheme and seek a judgment from the CFC. 42 U.S.C. 300aa-11(a)(2)-(3). If the claimant elects to reject that judgment (and any award), or with draws his petition after the special master or CFC fails to render a judgment within specified time peri ods, then the Act permits him to bring a civil action against the manufacturer. 42 U.S.C. 300aa-11(a)(2)(A), 300aa-21(a)-(b).
Such actions are governed by state law, subject to the Act's specific limitations. 42 U.S.C. 300aa-22. Among these limitations is the provision at issue here:
No vaccine manufacturer shall be liable in a civil ac tion for damages arising from a vaccine-related in jury or death associated with the administration of a vaccine after October 1, 1988, if the injury or death resulted from side effects that were unavoidable even though the vaccine was properly prepared and was accompanied by proper directions and warnings.
42 U.S.C. 300aa-22(b)(1).
2. Relative to the tens of millions of childhood vac cine doses administered annually, the number of peti tions in the CFC is small-reflecting the extraordinary safety of the covered vaccines. Since the first few years of the Compensation Program (which saw several thou sand claims for injuries that pre-dated the Act), there typically have been 100 to 200 ordinary claims filed an nually. Approximately one third of such claims are ulti mately compensated, with the average award exceeding $750,000. See Health Res. & Servs. Admin., Dep't of Health & Human Servs., National Vaccine Injury Com pensation Program Post-1988 Statistics Report (Dec. 2, 2009) <http://www.hrsa.gov/vaccinecompensation/ statistics_report.htm> (Statistics Report) .
Not counted among these ordinary claims are more than 5600 petitions asserting a causal link between childhood vaccines containing thimerosal (as well as cer tain measles-mumps-rubella (MMR) vaccines) and neu rological damage; approximately 5000 such petitions remain pending and have been consolidated before the CFC in the Omnibus Autism Proceeding (OAP). See Statistics Report. Six "test cases" were identified in the OAP to present two "general theor[ies] of causation." See Cedillo v. Secretary of HHS, No. 98-916V, 2009 WL 331968, at *9-10, *11 n.16 (Fed. Cl. Feb. 12, 2009), aff'd, 89 Fed. Cl. 158 (2009), appeal pending, No. 2010-5004 (Fed. Cir. filed Oct. 7, 2009). In the test cases present ing the first theory, special masters ruled that vaccines did not cause the claimants' injuries, and the CFC has affirmed those decisions. Ibid.; Hazlehurst v. Secretary of HHS, No. 03-654V, 2009 WL 332306 (Fed. Cl. Feb. 12, 2009), aff'd, 88 Fed.Cl. 473 (2009), appeal pending, No. 2009-5128 (Fed. Cir. filed Sept. 21, 2009); Snyder v. Sec retary of HHS, No. 01-162V, 2009 WL 332044 (Fed. Cl. Feb. 12, 2009), aff'd, 88 Fed. Cl. 706 (2009). In the test cases presenting the second theory of causation, the masters have held evidentiary hearings and received post-hearing briefing, and decisions are expected early this year. The CFC must decide each case in the omnibus proceeding individually (see 42 U.S.C. 300aa-12(d)(3), 300aa-13(a)), but the resolution of the test cases is expected to lead to efficient resolution of most of the remaining cases.
3. Respondents filed this action in state court against several vaccine manufacturers, including two of the petitioners here. Pet. App. 33-35; Compl. 2-3. The complaint alleged that respondents' son had suffered neurological injuries from exposure to vaccines pro duced by petitioners and approved by the Food and Drug Administration (FDA) that contained the preser vative thimerosal. Pet. App. 36. Petitioners moved for summary judgment, contending that respondents' claims are preempted by Section 22(b)(1). See id. at 34-37. As relevant here, the trial court granted that motion to the extent respondents' claims were based on the alleged design defect of using thimerosal. Id. at 49.
The Supreme Court of Georgia reinstated respon dents' claims. The Georgia court construed "unavoid able" in Section 22(b)(1) by looking to the 1986 Report, which commented on the text that became Section 22(b)(1). Pet. App. 7. That report states that Section 22(b)(1) was modeled on Restatement (Second) of Torts § 402A cmt. k (1965) (Comment k), which protects the seller of "unavoidably unsafe" products. Pet. App. 11 (quoting 1986 Report 26 (quoting Comment k)). The Georgia court read the reference to Comment k as show ing Congress's intent not to bar all design defect claims against vaccine manufacturers, but instead to allow ju ries to undertake a case-by-case analysis of whether a safer vaccine design was available. Id. at 7-10.
Pointing to the phrase "'if the [vaccine-related] in jury or death resulted from side effects that were un avoidable,'" the court observed that "[t]he conditional nature" of this language demonstrated that Congress contemplated "the occurrence of side effects which are avoidable, and for which a vaccine manufacturer may be civilly liable." Pet. App. 10 (first brackets in original) (quoting 42 U.S.C. 300aa-22(b)(1)). The court also relied on language in a post-enactment 1987 con gressional committee report on legislation that funded awards under the Compensation Program. Id. at 13-14. In the court's view, that report offered a "strikingly clear and emphatic" indication that Section 22(b)(1) was not a categorical bar to design defect claims. Id. at 14.
4. Six months after petitioners sought review in this Court, respondents voluntarily dismissed their claims in state court without prejudice. Resp. Supp. Br. App. 1a- 2a.
The Supreme Court of Georgia erred in holding that the Vaccine Act allows juries to resolve, on a case-by- case basis, claims that a vaccine approved by the FDA could have been designed in a way that would not have injured the plaintiff. That misunderstands the text of Section 22(b)(1), conflicts with the Act's legislative his tory, and frustrates Congress's intent to stabilize the market for vaccines critical to children's health. Con gress intended through Section 22(b)(1) to exempt vac cine manufacturers from design-defect liability, while still offering, through other provisions of the Act, com pensation to the injured and inducements to devise even safer vaccines.
The Georgia court's decision squarely conflicts with Bruesewitz v. Wyeth Inc., 561 F.3d 233, 242-243 (3d Cir. 2009), petition for cert. pending, No. 09-152 (filed Aug. 4, 2009). Moreover, the question presented is pressing. While it remains unsettled, manufacturers' uncertainty about their potential liability for design defects may harm the public health by deterring their development and production of vaccines. At the same time, thousands of claimants in the OAP do not know whether they may seek civil tort remedies. The issue therefore warrants this Court's review. Because of a mootness question in this case, however, the Court should grant the petition in Bruesewitz, which presents the same question.
I. THE GEORGIA SUPREME COURT MISINTERPRE TED THE VACCINE ACT'S PREEMPTIVE REACH
Section 22(b)(1) expressly preempts state law. See, e.g., Pet. App. 4; Bruesewitz, 561 F.3d at 242-243. The task therefore is to "identify the domain expressly pre- empted by that language." Medtronic v. Lohr, 518 U.S. 470, 484 (1996) (internal quotation marks and citation omitted). The preemptive reach of Section 22(b)(1) turns on what Congress intended to convey by invoking the term of art "unavoidable." The Georgia Supreme Court concluded that the term is "most consistent with" a case-by-case approach, under which a claim is not pre empted if a plaintiff can show that an injury from side effects was "avoidable by a feasible alternative design." Pet. App. 10-11. By contrast, petitioners contend that "unavoidable" conveys Congress's blanket determina tions that childhood vaccines, although offering immense social benefits, must be "deemed to be 'unavoidably un safe' because they carry an inherent risk of injury"- and that such products, in accordance with common law principles, should not expose their manufacturers to liability for design defects. Pet. 30. Petitioners' reading of Section 22(b)(1) is correct.2
1. Pointing to the phrase "if the injury or death re sulted from side effects that were unavoidable" (42 U.S.C. 300aa-22(b)(1)), the Georgia court concluded that "[t]he conditional nature of this clause contemplates the occurrence of side effects which are avoidable, and for which a vaccine manufacturer may be civilly liable." Pet. App. 10. From that premise, the court reasoned that claims based on avoidable design defects are not preempted, because if Congress had intended to bar all design defect liability, it could have said so more clearly. Id. at 10-11.
That approach to the statutory language is incorrect. "[I]t is always possible to construct through hindsight an alternate structure for a statute with alternative word ing that would render it more clear." Bruesewitz, 561 F.3d at 246. The more relevant question is what the best reading of the actual language is. Here, that lan guage indicates which side effects Congress thought avoidable and which it did not. The modifying clause be ginning "even though" explicates the universe of "avoid able" side effects-i.e., those caused by manufacturing defects or improper labeling. Side effects alleged to inhere in the vaccine's FDA-approved design are ex cluded from that list of "avoidable" side effects, for which civil liability is appropriate. The result is that Section 22(b)(1) bars one theory of liability (design de fect), while leaving in place two others (manufacturing and labeling defects), subject to other limitations in the Act.
2. The Act's legislative history supports this under standing. The 1986 Report explains (at 25-26) that "un avoidable" was drawn from Comment k, which concerns "[u]navoidably unsafe products." Restatement (Sec ond) of Torts § 402A cmt. k at 353 (1965) (caption). Comment k recognizes that "[t]here are some products which, in the present state of human knowledge, are quite incapable of being made safe for their intended and ordinary use," and offers a vaccine as a prototypical example. Ibid. Under Comment k, such a product is "not defective" as a matter of law, and the seller cannot be held liable for the consequences of its use as long as it was "properly prepared and marketed" and accompa nied by "proper warning." Id. at 354. Section 22(b)(1) codifies that rule.
The 1986 Report states that the Committee invoked Comment k "because it intends that the principle in Comment K regarding 'unavoidably unsafe' products * * * apply to the vaccines covered in the bill and that such products not be the subject of liability in the tort system." 1986 Report 26. In other words, vaccines cov ered by the Compensation Program would be deemed "unavoidably unsafe products," and thus not subject to design-defect claims. The 1986 Report further explains:
Given the existence of the [no-fault] compensation system in this bill, * * * [v]accine-injured persons will now have an appealing alternative to the tort system. Accordingly, if they cannot demonstrate under applicable law either that a vaccine was im properly prepared or that it was accompanied by im proper directions or inadequate warnings [they] should pursue recompense in the compensation sys tem, not the tort system.
The Georgia Supreme Court read this language as merely a prediction that vaccine claimants alleging de sign defects would find the new compensation system "appealing," despite being "authorized to [resort to] the tort system." Pet. App. 13. That misunderstands the Report in two ways. First, the Report does not say that claimants are "authorized" to pursue tort remedies; to the contrary, it states that such claimants "should * * * not" "pursue recompense in * * * the tort system." 1986 Report 26 (emphasis added). Second, the Georgia court's reading ignores the essential point of the quoted passage, which is that the Act treats design defect claims differently from claims based on manufacturing and labeling defects. Only the latter two theories can be pursued in the tort system.
To support its interpretation of Section 22(b)(1), the Georgia court also relied on language in a 1987 commit tee report that post-dated passage of the Act. Pet. App. 14 (citing H.R. Rep. No. 391, 100th Cong., 1st Sess. 691 (1987) (1987 Report)). According to that report, the cod ification of Comment k "was not intended to decide as a matter of law the circumstances in which a vaccine should be deemed unavoidably unsafe." 1987 Report 691. The report further stated that "[t]his question is left to the courts to determine in accordance with appli cable law." Ibid.
The 1987 Report is not persuasive authority for inter preting the Act as passed in 1986. It was prepared after Section 22(b)(1) became law. As this Court explained in District of Columbia v. Heller, 128 S. Ct. 2783 (2008), statements by those who drafted or voted for a law are relevant to statutory interpretation "not because they reflect the general understanding of the disputed terms, but because the legislators who heard or read those statements presumably voted with that understanding." Id. at 2805. Conversely, statements made after enact ment "could have had no effect on the congressional vote." Ibid. To be sure, Section 22(b)(1) did not become effective until the Compensation Program was funded by the appropriations that were the subject of the 1987 Report. See Br. in Opp. 20. But Members of Congress who voted for the Compensation Program and the asso ciated preemption provision in 1986 did so with the un derstanding not of some later document, but rather of the 1986 Report that vaccine design should "not be the subject of liability in the tort system." 1986 Report 26.3
3. Preemption of all design defect claims flows from the Act's structure and purpose as well. Fear of "insta bility and unpredictability of the childhood vaccine mar ket" due to the threat of large tort liability was an "overriding concern" that prompted the Act. 1986 Re port 7; see also Schafer v. American Cyanamid Co., 20 F.3d 1, 4 (1st Cir. 1994) (Breyer, C.J.) ("[A]n impor tant federal purpose of the Act is to free manufacturers from the specter of large, uncertain tort liability, and thereby keep vaccine prices fairly low and keep manu facturers in the market.").
The Act would do little to address this problem if it permitted any vaccine claimant disappointed with the CFC's judgment to seek all the customary product lia bility tort remedies in a civil action. Indeed, consistent with Comment k's statement of the law, no or few States in 1986 would have imposed tort liability on a vaccine manufacturer absent a showing by the plaintiff of a safer alternative design. Thus, on respondents' view of the Act, Congress intended to preempt liability only for con duct that state law probably would not have held tortious in the first place. That result does little to ad dress the burden of litigation or the threat of large and unpredictable tort judgments against vaccine manufac turers. At most, awards under the Compensation Pro gram might satisfy or dissuade some number of claim ants, somewhat reducing the number of potential civil tort plaintiffs.
Other parts of the Act also indicate that Congress intended more comprehensive and farther-reaching re form of the vaccine tort system than respondents sug gest. The Act achieves the principal goals of product- liability design defect law-compensation for the injured and incentives for safer products, see Wyeth v. Levine, 129 S. Ct. 1187, 1202 (2009)-by other means.
The Compensation Program provides relief through a system that is simpler and more generous than the tort system. See Shalala v. Whitecotton, 514 U.S. 268, 269 (1995); 1986 Report 6 ("[F]or the relatively few who are injured by vaccines * * * the opportunities for redress and restitution are limited, time-consuming, expensive, and often unanswered."). Significantly, the Vaccine Injury Table controls the scope of the Act for both compensation and preemption purposes, ensuring that compensation is potentially available whenever tort remedies are preempted.4
Safer vaccines are promoted through a rigorous FDA approval process. New childhood vaccines in particular are put through some of the most exhaustive examina tions and largest clinical trials of any FDA-approved product. For example, development of new vaccines for rotavirus gastroenteritis began in the early 1980s and, after clinical trials involving more than 130,000 partici pants, culminated in FDA approval in 2006 and 2007 of the vaccines. See Stanley A. Plotkin et al., Vaccines 719-720 (5th ed. 2008); Roger I. Glass & Umesh D. Para shar, The Promise of New Rotavirus Vaccines, 354 New Eng. J. Med. 75, 76 (2006). Each type of vaccine subject to the Act has been approved by the FDA as a biological product following such an extensive process, or is cur rently undergoing FDA-regulated clinical trials. See 42 U.S.C. 262(a).5
Vaccine safety and innovation are also encour aged through direct government funding of research. Government-wide statistics are not readily available, but the National Institutes of Health (NIH) alone reports funding about $1.5 billion of vaccine research per year. See NIH, Dep't of Health & Human Servs., Estimates of Funding for Various Research, Condition, and Dis ease Categories (rev. May 7, 2009) <http://report.nih. gov/rcdc/categories>. In addition, expert government agencies (such as the Centers for Disease Control and Prevention (CDC)) and nongovernmental organizations (such as the American Academy of Pediatrics) have sig nificant influence over the vaccines that are adminis tered to children.
The Act itself ensures continuous monitoring of vac cine safety by requiring that both vaccine manufacturers and health care providers report side effects (and other contraindicating reactions) to the Secretary through the Vaccine Adverse Event Reporting System. 42 U.S.C. 300aa-25(b); see http://vaers.hhs.gov. Mandatory re porting by health care providers of adverse events makes the reporting system for vaccines even more com prehensive than parallel systems applicable to drugs and non-vaccine biological products. Compare 42 U.S.C. 300aa-25(b) (vaccines), with 21 C.F.R. 600.80 (biological products generally), 21 U.S.C. 355(k)(1) (drugs), and 21 C.F.R. 314.80 (drugs).
Routinely administered vaccines are products for which the design trade-offs between safety and efficacy affect not only individual recipients, but also the entire society, which benefits from vaccines potent enough to ensure that a disease is contained or (as with smallpox) eradicated. See Schafer, 20 F.3d at 4. The tort sys tem-in which juries may pay little heed to this social cost/benefit calculus, see Riegel v. Medtronic, Inc., 128 S. Ct. 999, 1008 (2008)-is poorly equipped to en courage optimally safe and effective vaccines. That is why Congress recognized through the Act that expert regulators should control design decisions, with relief available under the Compensation Program.
II. THE SPLIT BETWEEN THE GEORGIA SUPREME COURT AND THE THIRD CIRCUIT MERITS THIS COURT'S ATTENTION
A. The Georgia Supreme Court's decision directly conflicts with the Third Circuit's decision in Bruesewitz, which held that Section 22(b)(1) preempts all design de fect claims. 561 F.3d at 235, 251, 255.
Bruesewitz concerns a child who experienced sei zures after her third dose of a diphtheria-tetanus-per tussis (DTP) vaccine. She ultimately suffered residual seizure disorder and developmental delay. Her parents pursued a timely but unsuccessful petition for compen sation in the CFC, Bruesewitz v. Secretary of HHS, No. 09-266V, 2002 WL 31965744 (Fed. Cl. Dec. 20, 2002), and rejected the CFC's judgment pursuant to 42 U.S.C. 300aa-21(a)(1). They then sued the manufacturer of the DTP vaccine in Pennsylvania state court, alleging (as relevant here) that toxins inherent in the vaccine's de sign caused their daughter's injuries. The manufacturer removed the case on the basis of diversity of citizenship, and the district court granted summary judgment for the manufacturer, holding that the Act preempted the plaintiffs' design-defect claims. See Bruesewitz, 561 F.3d at 236-238.
The Third Circuit affirmed. It began with the Act's text, which it read to preclude tort litigation over at least some design defect claims. Bruesewitz, 561 F.3d at 245. The court noted that Section 22(b)(1) "primarily relates to design defect claims," because the other types of products liability claims (i.e., for manufacturing or labeling defects) are dealt with in the "subordinate clause introduced by 'even though.'" Ibid. The Third Circuit rejected the Georgia court's textual analysis "because it does not bar any design defect claims"-that is, "[i]f we interpret the Vaccine Act to allow case-by- case analysis of whether particular vaccine side effects are avoidable, every design defect claim is subject to evaluation by a court." Id. at 246. The Third Circuit went on to conclude, based on legislative history, that the Act preempts all design defect claims irrespective of whether they sound in negligence or strict liability. Id. at 247-250.
Bruesewitz expressly rejects the reasoning of the Georgia Supreme Court. See Brueswitz, 561 F.3d at 248 ("In our view, the  Report supports the conclu sion that the Vaccine Act preempts all design defect claims."); id. at 246 ("[T]he Ferrari Court's construction [of Section 22(b)(1)] is contrary to the structure of the Act because it does not bar any design defect claims."); id. at 250 ("[W]e have no basis to conclude that the  Report is an accurate reflection of * * * the motivations underlying Congress's enactment of the Vaccine Act in 1986."). The conflict is thus squarely pre sented.6
B. The question presented is already informed by thorough analyses from several trial and appellate courts, and further attention from lower courts would contribute little to the debate. The issue has nationwide significance, and a decision from this Court would foster sound judicial administration and advance the public health, for three reasons in particular.
1. The question presented is important to more than 5000 claimants in the OAP currently pending before the CFC. To date, those claimants have been unsuccessful. If that remains the case, many may elect to pursue tort remedies against manufacturers. Efficient judicial ad ministration counsels early resolution of threshold legal issues likely to arise in those suits.
2. Fears of design defect liability could stall vaccine innovation while the law remains unsettled. Routine childhood vaccines typically have such a low rate of un avoidable serious side effects (sometimes numbering in the single digits per million doses) that they may not be discovered even in massive clinical trials. Public health would be undermined if manufacturers chose not to pur sue research and development of new vaccines for fear of unknown exposure to liability. Current research of fers several examples of vaccine development strategies that promise significant advantages in safety and effi cacy, but that may result in unknown rare side effects:
· Adjuvants. Currently, many childhood vaccines must be administered in multiple doses to confer lasting immunity. Adding certain compounds (known as adjuvants) to the vaccine may so im prove the immune response that fewer doses are needed. See, e.g., P. Helena Mäkelä, Vaccines, Coming of Age After 200 Years, 24 FEMS Micro biology Rev. 9, 14-15 (2000) (Vaccines, Coming of Age). This strategy would avoid underimmuni zation due to missed doses and permit faster re sponses to epidemics. But conceivably the adjud vant might provoke a rare side effect-one the Georgia court might label "avoidable" because the vaccine could have been administered without the adjuvant.
· Cell-based influenza vaccine. Currently, many influenza vaccines-including most for seasonal influenza-are produced in chicken eggs, a pro cess that takes several months. Vaccines 266. Novel and much more rapid cell-based approach es to producing influenza vaccines are under de velopment. See Ibid.; Nat'l Inst. of Allergy & Infectious Diseases, Dep't of Health & Human Servs., The Jordan Report: Accelerated Develop ment of Vaccines 2007, App. A at 132 (May 2007). The ability to begin production closer to the flu season would improve the accuracy of predicting which strains will be dominant in a given year, and would allow manufacturers to respond to late-appearing strains. See Manon M.J. Cox, Cell-Based Protein Vaccines for Influenza, 7 Current Opinion in Molecular Therapeutics 24, 24-26 (2005). Faster production would also allow swifter response to pandemic flu outbreaks. See id. at 26; Homeland Sec. Council, National Strat egy for Pandemic Influenza: Implementation Plan 105 n.16 (May 2006). But as with any new technique, cell-based approaches to producing vaccines could have side effects-and the Georgia court could label these side effects "avoidable" because the vaccines could instead have been pro duced using chicken eggs.
· DNA vaccines. Most vaccines work by introduc ing a harmless substance (such as a partial or inactivated virus or toxin) that teaches the body to recognize the molecular characteristics of a pathogen, so that the immune system will react swiftly in response to a true threat. See CDC, Dep't of Health & Human Servs., How Vaccines Prevent Disease (last modified Aug. 7, 2009) <http://www.cdc.gov/vaccines/vac-gen/howvpd. htm>. DNA vaccines operate by introducing DNA sequences that prompt the body itself to make a small amount of the teaching substance. See Vaccines, Coming of Age 15-16. The tech nique promises new vaccines and more effective versions of existing vaccines. See Jordan Report App. A (listing DNA vaccines under develop ment). But any side effects could be "avoidable" on the Georgia court's view if an injured party could point to the older version of the vaccine as an alternative.
3. Withdrawal of a manufacturer from the vaccine market for fear of design defect liability could have sub stantial public health consequences. As noted above, the Congress that passed the Act was concerned about just such instability and unpredictability in the vaccine mar ket. Congress anticipated that the Act would give manu facturers "a better sense of their potential litigation obli gations" and that, as a result, "a more stable childhood vaccine market [would] evolve," 1986 Report 7. But as amici the American Academy of Pediatrics et al. stress (Br. 19-20), vaccines still are produced by very few man ufacturers.
The Georgia court's decision could affect the existing balance. To be sure, predicting what a vaccine manufac turer might do in the future is inherently speculative. Manufacturers' potential liability for cases like this one and Bruesewitz lies principally in past events. The DTP vaccine that allegedly caused the Bruesewitz plaintiffs' daughter's injuries is no longer administered to children in the United States; similarly, the preservative thimer osal, which allegedly caused respondents' son's injuries, is no longer used in vaccines routinely administered to infants and young children in the United States.7 But the withdrawal in the future of even one of the handful of manufacturers producing vaccines could lead to a vac cine shortage. That shortage would not only risk dis ease for those left unvaccinated, but create conditions in which disease could run freely throughout the commu nity. That is because vaccines are administered not only to immunize individuals, but also "to reduce transmis sion of infection and thereby to prevent disease even in non-vaccinated individuals, thus to protect communi ties." Vaccines 1573.8
III. BRUESEWITZ IS THE APPROPRIATE VEHICLE FOR RESOLUTION OF THE QUESTION PRESENTED
Respondents' voluntary dismissal in state court raises a substantial question concerning mootness that did not exist when this Court called for this Office's views. See Resp. Supp. Br. 1-2; Pet. Supp. Br. 3-5. Peti tioners are correct that the Court has occasionally found a case to remain live notwithstanding post-petition de velopments that seemingly ended the controversy be tween the parties. But none of the cases the parties cite from this Court's mootness jurisprudence squarely ad dresses the precise situation here. See City News & Novelty, Inc. v. City of Waukesha, 531 U.S. 278, 282-286 (2001); City of Erie v. Pap's A.M., 529 U.S. 277, 288 (2000); Deakins v. Monaghan, 484 U.S. 193, 199-201 (1988). And no party suggests the threshold mootness question is independently certworthy.
Because Bruesewitz is a suitable alternative vehicle, the Court can address the important legal question here while avoiding the mootness issue. Bruesewitz appears jurisdictionally sound,9 and the questions presented in that case and this one are materially identical. The claims in Bruesewitz (which involve administration of a particular DTP vaccine) are not representative of the claims in the OAP (which involve administration of MMR and thimerosal-containing vaccines), but that dif ference is legally immaterial. Organizations aligned with OAP claimants would likely present their views as amici curiae in Bruesewitz-as they have already done at the petition stage, see National Vaccine Information Center et al. Amici Br. 2, Bruesewitz, supra. Likewise, manufacturers of vaccines at issue in the OAP would be able to present their views in Bruesewitz.
Accordingly, the Court should grant the petition in Bruesewitz. The Court could hold the petition in this case pending Bruesewitz, or else simply deny the peti tion to avoid the idiosyncratic mootness question, cf. ASARCO Inc. v. Kadish, 490 U.S. 605, 621 n.1 (1989).
The petition for a writ of certiorari should be held pending the disposition of Bruesewitz v. Wyeth, Inc., petition for cert. pending, No. 09-152, or be denied. The petition for a writ of certiorari in Bruesewitz should be granted.
Respectfully submitted.ELENA KAGAN
1 The Secretary maintains the Table at 42 C.F.R. 100.3. To be in cluded on the Table, a category of vaccine must be "recommended for routine administration to children" by the Centers for Disease Control and Prevention, 42 U.S.C. 300aa-14(e)(2) and (2)(A), and Congress must fund awards by subjecting the category of vaccine to the excise tax, Act of Aug. 10, 1993, Pub. L. No. 103-66, § 13632(a)(3), 107 Stat. 646.
2 Because Section 22(b)(1) is an express preemption provision, Wyeth v. Levine, 129 S. Ct. 1187, 1193 (2009), which concerned implied preemption, is of limited relevance. Moreover, the precise question in Levine was whether federal drug labeling law impliedly preempted the plaintiff's claim that a drug should have borne more stringent warnings than approved by FDA. The Act here speaks directly to vaccine label ing by providing that a vaccine that complies with all FDA require ments "shall be presumed to be accompanied by proper directions and warnings." 42 U.S.C. 300aa-22(b)(2).
3 The 1987 Report also states (at 691) that when the House Commit tee on Energy and Commerce considered the original act in 1986, it re jected an amendment providing that "a manufacturer's failure to de velop a safer vaccine was not grounds for liability." See House Energy & Commerce Comm., Markup Hearing on H.R. 5546, at 46-54 (Sept. 18, 1986) (rejecting amendment). The proceedings within a single commit tee's markup session are likewise not an authoritative guide to what Congress understood and intended in passing a bill. Rather, "the au thoritative source for finding the Legislature's intent lies in the Com mittee Reports on the bill." Eldred v. Ashcroft, 537 U.S. 186, 210 n.16 (2003) (quoting Garcia v. United States, 469 U.S. 70, 76 (1984)).
4 The Compensation Program requires proof that the injured party received a vaccine on the Table. See 42 U.S.C. 300aa-11(c)(1)(A), 300aa-13(a)(1)(A). As for preemption, Section 22(b)(1) preempts only claims for "vaccine-related injury or death," which is by definition limi-
ted to injuries "associated with one or more of the vaccines set forth in the Vaccine Injury Table," 42 U.S.C. 300aa-33(5).
5 Conceivably some vaccines administered abroad to federal employ ees and their dependents would be covered by the Act, see 42 U.S.C. 300aa-11(c)(1)(B)(i)(II), but not subject to FDA regulation.
6 Respondents would avoid the conflict by confining Bruesewitz's holding to preemption of DTP design-defect claims, based on the Third Circuit's observation (561 F.3d at 250) that Congress was particularly concerned with DTP-related claims in passing the Act. See Br. in Opp. 21. But the distinction respondents perceive would dismiss nearly all of the Third Circuit's analysis as dicta, and that distinction has no basis in the law. The Act draws only one relevant distinction: between vac cines that are on the Table and those that are not. See, e.g., 42 U.S.C. 300aa-11(c)(1)(A) and 300aa-33(5).
7 The exceptions to this are certain influenza vaccines pre served with thimerosal, and certain other vaccines containing trace amounts of thimerosal. See FDA, Dep't of Health & Human Servs., Thimerosal in Vaccines tbl. 1 (last modified Nov. 6, 2009) <http://www. fda.gov/BiologicsBloodVaccines/SafetyAvailability/VaccineSafety/ ucm096228.htm>.
8 Congress and the Secretary have demonstrated a similar concern in responding to threats like the H1N1 influenza pandemic. See 42 U.S.C. 247d-6d (added by Public Readiness and Emergency Pr eparedness Act, Pub. L. No. 109-146, Div. C, § 2, 119 Stat. 2818) (bar ring liability for designated vaccines and other countermeasures, except for cases of "willful misconduct"); 74 Fed. Reg. 30,294 (2009) (designat ing H1N1 vaccines-which, unlike the trivalent seasonal influenza vaccine, are not subject to the Vaccine Act-for such protection).
9 The Bruesewitz plaintiffs challenged the defendant manufacturer's removal of the case to federal court on diversity of citizenship grounds, asserting that all parties were Pennsylvania citizens. Applying the Third Circuit's multi-factor "center of corporate activities" test to de cide the manufacturer's "principal place of business," the district court concluded that the manufacturer was a citizen of New Jersey (and Dela ware, where it is incorporated), and thus diverse. Bruesewitz v. Wyeth, Inc., No. 05-5994, Docket entry No. 13 (E.D. Pa. Mar. 27, 2006).
This Court's decision in Hertz Corp. v. Friend, No. 08-1107 (argued
Nov. 10, 2009)-which concerns the test for deciding a corporation's "principal
place of business" under 28 U.S.C. 1332(c)(1)-is unlikely to nullify
the district court's jurisdiction in Bruesewitz. The manufacturer (whose
executive offices are in New Jersey) would certainly be a citizen of New
Jersey under the Hertz petitioner's proposed "headquarters" test,
and likely would also be a citizen of that State under the Hertz respondent's
proposed multi-factor test.